Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
Yoshiaki NakamuraRiu YamashitaWataru OkamotoYoshito KomatsuSatoshi YukiMakoto UenoKen KatoHiroya TaniguchiYoshinori KagawaTadamichi DendaHiroki HaraTaito EsakiToshikazu MoriwakiYu SunakawaEiji OkiFumio NagashimaTomohiro NishinaTaroh SatohHiasto KawakamiKensei YamaguchiKoushiro OhtsuboTakeshi KatoYosuke HoritaAkihito TsujiHisateru YasuiMasahiro GotoYasuo HamamotoMasashi WakabayashiTakashi IkenoKohei ShitaraHideaki BandoKatsuya TsuchiharaIzumi MikiHiroko IchikiAtsushi OhtsuTakayuki YoshinoPublished in: JCO precision oncology (2023)
Our genomic profiling program led to patient enrollment in targeted clinical trials and improved survival of patients with colorectal cancer who received matched therapies in clinical trials. To avoid immortal time bias, precautions are needed when using data from patients who have undergone NGS testing after initiation of the evaluated treatment line.
Keyphrases
- clinical trial
- end stage renal disease
- signaling pathway
- single cell
- ejection fraction
- chronic kidney disease
- cancer therapy
- newly diagnosed
- quality improvement
- copy number
- prognostic factors
- peritoneal dialysis
- case report
- high throughput
- patient reported outcomes
- epithelial mesenchymal transition
- phase ii
- randomized controlled trial
- pi k akt
- dna methylation
- health insurance
- healthcare
- oxidative stress
- drug delivery
- machine learning
- gene expression
- patient reported
- smoking cessation
- phase iii
- free survival
- artificial intelligence